Breast Cancer Trial, Not Yet Recruiting NCT06798506 Sponsor: Fudan University Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Not Yet Recruiting

NCT06798506
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who are over 18 years old.
  • People who have been diagnosed with metastatic triple-negative breast cancer (mTNBC), meaning their breast cancer has spread and has tested negative for three specific markers (ER, PgR, and HER2), as confirmed by lab testing of tumour tissue.
  • People whose cancer spreading to other parts of the body has been confirmed through clinical assessment, scans, or tissue/fluid testing — this includes breast cancer that cannot be surgically removed, breast cancer that was already at an advanced stage when first diagnosed, or breast cancer that has come back and spread.
  • People who have already received at least one treatment for their cancer after it became metastatic (spread to other parts of the body).
  • People who are planning to receive, or have already received, either a drug called sacituzumab govitecan on its own, or another chemotherapy treatment chosen by their doctor.
  • People who have medical history records available.
  • People who are able to provide their consent to participate before joining the trial and having their data collected.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who are currently taking part in another controlled clinical trial.
  • People whose breast cancer shows a high level of the HER2 protein or an increase in the HER2 gene, as confirmed by specific lab tests (confirm with trial site).
  • People who are pregnant or breastfeeding.
  • People who have severe liver problems.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +86 13701748410

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
15 February 2025
Est. completion
15 January 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Patient-reported HRQOL

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov